Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910882 · ClinicalTrials.gov registry record · Phase 2
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
A Phase 2 study, sponsored by Scripps Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02910882 is a Phase 2 study that was terminated before completion, run by Scripps Health. The registered enrollment target is 4 participants.
The verdict
NCT02910882, a Phase 2 study, was terminated before completion, sponsored by Scripps Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.
Interventions
- DRUG Gemcitabine
- RADIATION Radiation
- DRUG PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-01-03 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910882
The ClinicalTrials.gov registry entry for NCT02910882 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scripps Health, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02910882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02910882 about?
NCT02910882 is a clinical study titled "PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer". This is a single arm phase II trial assessing the potential activity of combination PEGPH20 plus Gemcitabine with radiotherapy in ten patients with localized, unresectable pancreatic adenocarcinoma.
What is the current status of trial NCT02910882?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2017-01-03. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT02910882?
The interventions under investigation include: Gemcitabine (DRUG), Radiation (RADIATION), PEGylated Recombinant Human Hyaluronidase (PEGPH20) (DRUG).
Who is sponsoring clinical trial NCT02910882?
This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.